Teplizumab on the NHS: What Community Pharmacists Need to Know

What happened

NICE issued final draft guidance on 23 June 2026 recommending teplizumab (brand name Tzield, manufactured by Sanofi) for NHS use as the first disease-modifying therapy to delay the onset of symptomatic type 1 diabetes.¹ England is the first country in Europe where teplizumab has been recommended through a health technology appraisal. This is final draft guidance: the 90-day NHS access period in England will run from the date of final published NICE guidance, which has not yet been confirmed.⁷ In Wales, the 60-day access period runs from 23 June 2026.¹

Type 1 diabetes progresses through three stages. At stage 1, the immune system has begun attacking the insulin-producing cells of the pancreas, but blood sugar levels are normal and there are no symptoms. At stage 2, two or more pancreatic islet autoantibodies are present and blood sugar levels show early changes (dysglycaemia) on glucose tolerance testing, but the person still has no symptoms and does not yet need insulin. At stage 3, symptoms appear and most people receive their clinical diagnosis, requiring lifelong insulin treatment. Teplizumab is used at stage 2 to delay the onset of stage 3.³

NICE reports that the TN-10 clinical trial showed teplizumab delayed the onset of symptomatic type 1 diabetes by approximately 32 months. In the trial, the median time to stage 3 diagnosis was 50 months with teplizumab versus 25 months with placebo.¹ Around 1,100 people are expected to be eligible in England in the first year, stabilising to approximately 820 per year from year 3 onwards. Teplizumab is not suitable for established stage 3 type 1 diabetes or type 2 diabetes.

What this means for pharmacy

Community pharmacists will not supply or administer teplizumab. It will be given in specialist hospital settings only. The BBC coverage and wider news attention mean pharmacists are likely to receive questions from patients and families who want to understand eligibility, how the drug works, and where to seek assessment.⁶

Pharmacy action points: (1) Do not offer screening, diagnosis, prescribing, supply, or administration of teplizumab in community pharmacy. (2) Signpost asymptomatic people interested in screening, especially those with a family history of type 1 diabetes, to the ELSA study, T1DRA study, or their GP/diabetes specialist. (3) Any patient presenting with possible symptoms of diabetes needs urgent medical assessment, not signposting to a research screening programme. Teplizumab questions should not distract from urgent recognition of new symptomatic diabetes; symptomatic patients need medical assessment, not screening signposting. (4) If a patient has symptoms of possible diabetic ketoacidosis, act immediately (see below). (5) Explain that teplizumab is a specialist hospital medicine and that eligibility requires specialist confirmation, not just a positive autoantibody screening result.

"Can I or my child get this treatment?" Stage 2 type 1 diabetes has no symptoms, so most people will not know they have it unless they have been screened or are already in a research study. Eligibility requires two or more positive pancreatic islet autoantibodies plus confirmed dysglycaemia on oral glucose tolerance testing, assessed by a specialist. This cannot be identified or initiated in community pharmacy. The right starting point is a GP or diabetes specialist, particularly if the patient has a close relative (parent, sibling, or child) with type 1 diabetes.²

"How does someone find out if they are eligible?" Two research studies currently provide access to autoantibody screening in the UK. The ELSA study (elsadiabetes.nhs.uk) screens children aged 2 to 17 and is funded by Diabetes UK and Breakthrough T1D.⁴,⁸ The T1DRA study (t1dra.bristol.ac.uk) is open to adults aged 18 to 70.²,⁹ People with a close relative with type 1 diabetes may also be referred through routine clinical routes. Anyone with a positive autoantibody test is encouraged to join the UK Islet Autoantibody Registry, which provides specialist follow-up, support from specialist nurses, and information about research and treatment opportunities.⁵ The NHS is developing new testing and treatment pathways as teplizumab becomes available.

Important: symptoms are not a route to screening. Patients presenting with possible symptoms of type 1 diabetes, such as increased thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, genital itching, or thrush, need GP or NHS 111 assessment, not signposting to the ELSA or T1DRA studies. These studies are for asymptomatic people identified through family history or incidental testing. Do not delay urgent medical assessment by directing symptomatic patients toward a research screening pathway.

DKA escalation: if a child or adult has possible diabetes symptoms along with vomiting, abdominal pain, drowsiness, dehydration, deep or rapid breathing, or collapse, treat as a possible diabetic ketoacidosis emergency. If the patient is present in the pharmacy, call 999. If advice is being given remotely and DKA symptoms are described, advise immediate emergency care or 999.²

"Will this cure my child's diabetes?" No. NICE reports teplizumab delayed the onset of symptomatic type 1 diabetes by approximately 32 months. The person is still expected to develop stage 3 type 1 diabetes and eventually require insulin. It does not prevent or cure the condition, but offers extra time before the lifelong demands of insulin management begin.¹,³

"Can someone who already has type 1 diabetes take it?" No. Teplizumab is only for stage 2 type 1 diabetes, the pre-symptomatic stage before insulin is needed. It is not a treatment for established stage 3 type 1 diabetes or for type 2 diabetes.³

"When will it be available?" In Wales, NHS services must be available within 60 days of 23 June 2026. In England, the 90-day access clock starts when NICE publishes final guidance; the final publication date has not yet been confirmed.⁷ Scotland uses the SMC, with advice expected in early 2027. Northern Ireland has a separate process for adopting NICE guidance and timelines are not yet confirmed.¹,²

Key takeaways

• Teplizumab (Tzield) is the first treatment recommended in NICE final draft guidance for NHS use to delay the onset of insulin-dependent type 1 diabetes. It is for pre-symptomatic stage 2 only (two or more pancreatic islet autoantibodies plus confirmed dysglycaemia) and will not be supplied or administered in community pharmacy.
• Patients or families asking about eligibility should be directed to their GP or diabetes specialist. Autoantibody screening is available via the ELSA study for children aged 2 to 17 (elsadiabetes.nhs.uk) or the T1DRA study for adults aged 18 to 70 (t1dra.bristol.ac.uk). Anyone with a positive autoantibody test should be encouraged to join the UK Islet Autoantibody Registry for specialist follow-up.
• Teplizumab does not cure or prevent type 1 diabetes and is not suitable for established stage 3 type 1 diabetes or type 2 diabetes. Patients presenting with possible diabetes symptoms need medical assessment, not research screening. If DKA symptoms are present in the pharmacy, call 999.